Alumis Inc. (ALMS) News
Follow Alumis Inc. (ALMS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
ALMS progress on envudeucitinib in lupus and psoriasis programs
Envudeucitinib’s phase II lupus trial failed overall, but showed strong efficacy in interferon signature positive patients. Plans are underway for a phase III lupus trial focused on those patients; psoriasis development
EQUITY | Sep 08, 2026, 05:11 PM UTC
M
ALMS: Envudicitinib shows efficacy in lupus and psoriasis subgroups
ALMS said its phase IIb lupus trial failed overall, citing a high proportion of interferon signature negative patients, but showed strong efficacy in interferon signature positive subgroups. Regulatory discussions are pl
EQUITY | Sep 08, 2026, 04:15 PM UTC
M
Alumis (ALMS) tumbles on Phase 2b LUMUS endpoint miss
Alumis Inc. shares plunged about 57% after Phase 2b LUMUS missed overall primary and key secondary endpoints, though the high–interferon subgroup met them. HC Wainwright upgraded and cut its target to $15; Wells Fargo cu
EQUITY | Sep 07, 2026, 11:22 AM UTC
L
Alumis to participate in September investor conferences
Alumis Inc. (ALMS) announced it will participate in upcoming September investor conferences.
EQUITY | Sep 04, 2026, 12:07 PM UTC
L
ALMS - Alumis to Participate in Upcoming September Investor Conferences
ALMS - Alumis to Participate in Upcoming September Investor Conferences
EQUITY | Sep 04, 2026, 12:00 PM UTC
L
Guggenheim cuts Alumis to Neutral
Guggenheim downgraded Alumis to Neutral from Buy, according to Benzinga ratings actions.
EQUITY | Sep 03, 2026, 01:46 PM UTC
L
Oppenheimer cuts Alumis price target to $37
Oppenheimer maintained Alumis as Outperform but cut its price target to $37.00 a share from $55.00, according to Benzinga ratings actions.
EQUITY | Sep 02, 2026, 05:02 PM UTC
L
Wells Fargo cuts Alumis price target, maintains overweight rating
Wells Fargo maintained an overweight rating on Alumis while cutting its price target to $25.00 from $51.00.
EQUITY | Sep 02, 2026, 02:40 PM UTC
L
Morgan Stanley keeps Alumis at Overweight; cuts price target
Morgan Stanley maintained Alumis at Overweight and cut its price target to $29.00 from $39.00.
EQUITY | Sep 02, 2026, 12:30 PM UTC
L
HC Wainwright cuts Alumis price target to $15 from $25
HC Wainwright & Co. cut its price target on Alumis to $15.00 per share from $25.00, according to Benzinga ratings actions.
EQUITY | Sep 02, 2026, 11:30 AM UTC
H
ALMS plunges 57% after lupus Phase 2b topline misses goals
Alumis Inc. shares fell 57% Tuesday, its worst day since the mid-2024 IPO, after topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus missed the study’s main goals.
EQUITY | Sep 01, 2026, 11:55 PM UTC
H
Alumis stock slides after envudeucitinib misses lupus trial goal
Alumis shares were pacing for a worst day on record after the company said its lupus drug candidate, envudeucitinib, failed to meet the main goal in a mid-stage trial.
EQUITY | Sep 01, 2026, 05:23 PM UTC
M
ALMS trial update: envudeucitinib shows subgroup efficacy in SLE
LUMUS Phase 2b in SLE did not meet primary endpoints overall, but robust efficacy was reported in the IFNGS-high subgroup. Envudeucitinib was described as well tolerated, with Phase 3 plans underway.
EQUITY | Sep 01, 2026, 02:24 PM UTC
M
ALMS: Envudeucitinib misses endpoints overall; strong IFNGS-high subgroup results
Envudeucitinib did not meet primary or secondary endpoints in the overall SLE population, but showed robust efficacy and a favorable safety profile in the IFNGS-high subgroup. Future development will focus there, with re
EQUITY | Sep 01, 2026, 02:03 PM UTC
M
ALMS envudeucitinib misses SLE endpoints overall; strong IFNGS-high subgroup
Alms’ phase IIb LUMUS trial of envudeucitinib in SLE did not meet primary or secondary endpoints overall. The IFNGS-high subgroup showed robust efficacy for phase III focus; safety was favorable, with regulatory engageme
EQUITY | Sep 01, 2026, 01:47 PM UTC
M
Alumis trial of lupus drug fails to meet endpoints
Alumis said its phase 2b trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints, including the goal for overall disease activity improvements.
EQUITY | Sep 01, 2026, 01:32 PM UTC
M
Alumis reports LUMUS topline, misses overall endpoints
Alumis said LUMUS Phase 2b topline results missed primary and secondary endpoints overall, but showed robust responses in IFNGS-high patients.
REGULATION | Sep 01, 2026, 12:34 PM UTC
M
Alumis reports Phase 2b envudeucitinib results in SLE
Alumis said its Phase 2b results for envudeucitinib in SLE did not meet endpoints overall, but strong efficacy was seen in the IFNGS-high subgroup. The drug was well tolerated and supports Phase 3 plans.
EQUITY | Sep 01, 2026, 12:29 PM UTC
L
ALMS announces topline results from Envudeucitinib Phase 2b in SLE
Alumis said it has topline initial high-level results from its Envudeucitinib Phase 2b trial in systemic lupus erythematosus (SLE).
EQUITY | Sep 01, 2026, 11:37 AM UTC
L
ALMS: Alumis reports Q2 2026 financial results
Alumis (ALMS) reports its second-quarter 2026 financial results and highlights recent achievements, per TradeXchange Newsdesk.
EARNINGS | Aug 13, 2026, 08:01 PM UTC